In vitro targeting of Polo-like kinase 1 in bladder carcinoma

References

• Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, Center MM, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008; 100:1672 - 94; http://dx.doi.org/10.1093/jnci/djn389; PMID: 19033571
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Yagoda A, Scher HI, Watson RC, Herr HW, Morse MJ, et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 1988; 139:461 - 9; PMID: 3343727
   PubMed Web of Science ®Google Scholar
• Kaufman DS. Challenges in the treatment of bladder cancer. Ann Oncol 2006; 17:Suppl 5 v106 - 12; http://dx.doi.org/10.1093/annonc/mdj963; PMID: 16807436
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Matsuyama H, Kawauchi S, Matsumoto H, Nagao K, Ohmi C, et al. Overexpression of polo-like kinase 1 (PLK1) and chromosomal instability in bladder cancer. Oncology 2006; 70:231 - 7; http://dx.doi.org/10.1159/000094416; PMID: 16837776
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang G, Kong C. High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder. Urol Oncol 2011; PMID: 22192978
   PubMed Web of Science ®Google Scholar
• Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 2010; 9:643 - 60; http://dx.doi.org/10.1038/nrd3184; PMID: 20671765
   PubMed Web of Science ®Google Scholar
• Fristrup N, Ulhøi BP, Birkenkamp-Demtröder K, Mansilla F, Sanchez-Carbayo M, Segersten U, et al. Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer. Am J Pathol 2012; 180:1824 - 34; http://dx.doi.org/10.1016/j.ajpath.2012.01.023; PMID: 22449953
   PubMed Web of Science ®Google Scholar
• Steegmaier M, Hoffmann M, Baum A, Lénárt P, Petronczki M, Krssák M, et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007; 17:316 - 22; http://dx.doi.org/10.1016/j.cub.2006.12.037; PMID: 17291758
   PubMed Web of Science ®Google Scholar
• Schmit TL, Zhong W, Setaluri V, Spiegelman VS, Ahmad N. Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells. J Invest Dermatol 2009; 129:2843 - 53; http://dx.doi.org/10.1038/jid.2009.172; PMID: 19554017
   PubMed Web of Science ®Google Scholar
• Winkles JA, Alberts GF. Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues. Oncogene 2005; 24:260 - 6; http://dx.doi.org/10.1038/sj.onc.1208219; PMID: 15640841
   PubMed Web of Science ®Google Scholar
• Nogawa M, Yuasa T, Kimura S, Tanaka M, Kuroda J, Sato K, et al. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest 2005; 115:978 - 85; PMID: 15761500
   PubMed Web of Science ®Google Scholar
• Seth S, Matsui Y, Fosnaugh K, Liu Y, Vaish N, Adami R, et al. RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer. Mol Ther 2011; 19:928 - 35; http://dx.doi.org/10.1038/mt.2011.21; PMID: 21364537
   PubMed Web of Science ®Google Scholar
• Renner AG, Dos Santos C, Recher C, Bailly C, Créancier L, Kruczynski A, et al. Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood 2009; 114:659 - 62; http://dx.doi.org/10.1182/blood-2008-12-195867; PMID: 19458358
   PubMed Web of Science ®Google Scholar
• Morales AG, Brassesco MS, Pezuk JA, Oliveira JC, Montaldi AP, Sakamoto-Hojo ET, et al. BI 2536-mediated PLK1 inhibition suppresses HOS and MG-63 osteosarcoma cell line growth and clonogenicity. Anticancer Drugs 2011; 22:995 - 1001; PMID: 21822121
   PubMed Web of Science ®Google Scholar
• Liu X, Choy E, Harmon D, Yang S, Yang C, Mankin H, et al. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo. Anticancer Drugs 2011; 22:444 - 53; http://dx.doi.org/10.1097/CAD.0b013e32834513f4; PMID: 21399492
   PubMed Web of Science ®Google Scholar
• Schmit TL, Zhong W, Setaluri V, Spiegelman VS, Ahmad N. Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells. J Invest Dermatol 2009; 129:2843 - 53; http://dx.doi.org/10.1038/jid.2009.172; PMID: 19554017
   PubMed Web of Science ®Google Scholar
• Ikezoe T, Yang J, Nishioka C, Takezaki Y, Tasaka T, Togitani K, et al. A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies. Leukemia 2009; 23:1564 - 76; http://dx.doi.org/10.1038/leu.2009.94; PMID: 19421227
   PubMed Web of Science ®Google Scholar
• Plyte S, Musacchio A. PLK1 inhibitors: setting the mitotic death trap. Curr Biol 2007; 17:R280 - 3; http://dx.doi.org/10.1016/j.cub.2007.02.018; PMID: 17437704
   PubMedGoogle Scholar
• Vakifahmetoglu H, Olsson M, Zhivotovsky B. Death through a tragedy: mitotic catastrophe. Cell Death Differ 2008; 15:1153 - 62; http://dx.doi.org/10.1038/cdd.2008.47; PMID: 18404154
   PubMed Web of Science ®Google Scholar
• Reznikoff CA, Belair CD, Yeager TR, Savelieva E, Blelloch RH, Puthenveettil JA, et al. A molecular genetic model of human bladder cancer pathogenesis. Semin Oncol 1996; 23:571 - 84; PMID: 8893868
   PubMed Web of Science ®Google Scholar
• da Silva GN, de Castro Marcondes JP, de Camargo EA, da Silva Passos Júnior GA, Sakamoto-Hojo ET, Salvadori DM. Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine. Exp Biol Med (Maywood) 2010; 235:814 - 24; http://dx.doi.org/10.1258/ebm.2010.009322; PMID: 20558835
   PubMed Web of Science ®Google Scholar
• Gleixner KV, Ferenc V, Peter B, Gruze A, Meyer RA, Hadzijusufovic E, et al. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. Cancer Res 2010; 70:1513 - 23; http://dx.doi.org/10.1158/0008-5472.CAN-09-2181; PMID: 20145140
   PubMed Web of Science ®Google Scholar
• Wolf S, Lorenz J, Mössner J, Wiedmann M. Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance. World J Gastroenterol 2010; 16:156 - 66; http://dx.doi.org/10.3748/wjg.v16.i2.156; PMID: 20066734
   PubMed Web of Science ®Google Scholar
• Stewart HJ, Kishikova L, Powell FL, Wheatley SP, Chevassut TJ. The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma. Exp Hematol 2011; 39:330 - 8; http://dx.doi.org/10.1016/j.exphem.2010.12.006; PMID: 21184800
   PubMed Web of Science ®Google Scholar
• Didier C, Cavelier C, Quaranta M, Demur C, Ducommun B. Evaluation of Polo-like Kinase 1 inhibition on the G2/M checkpoint in Acute Myelocytic Leukaemia. Eur J Pharmacol 2008; 591:102 - 5; http://dx.doi.org/10.1016/j.ejphar.2008.06.062; PMID: 18616938
   PubMed Web of Science ®Google Scholar
• Deckbar D, Jeggo PA, Löbrich M. Understanding the limitations of radiation-induced cell cycle checkpoints. Crit Rev Biochem Mol Biol 2011; 46:271 - 83; http://dx.doi.org/10.3109/10409238.2011.575764; PMID: 21524151
   PubMed Web of Science ®Google Scholar
• Rödel F, Keppner S, Capalbo G, Bashary R, Kaufmann M, Rödel C, et al. Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer. Am J Pathol 2010; 177:918 - 29; http://dx.doi.org/10.2353/ajpath.2010.100040; PMID: 20581060
   PubMed Web of Science ®Google Scholar
• Bordon E, Leon LG, Rios-Luci C, Lara PC, Padron JM. In vitro synergistic interaction between DTA0100 and radiation in human cancer cell lines. Anticancer Agents Med Chem 2012; 12:988 - 93; http://dx.doi.org/10.2174/187152012802650057; PMID: 22339062
   PubMed Web of Science ®Google Scholar
• Heravi M, Tomic N, Liang L, Devic S, Holmes J, Deblois F, et al. Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model. Anticancer Drugs 2012; 23:525 - 33; http://dx.doi.org/10.1097/CAD.0b013e32834ea5b3; PMID: 22357220
   PubMed Web of Science ®Google Scholar
• Gerster K, Shi W, Ng B, Yue S, Ito E, Waldron J, et al. Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2010; 77:253 - 60; http://dx.doi.org/10.1016/j.ijrobp.2009.11.027; PMID: 20394857
   PubMed Web of Science ®Google Scholar
• Harris PS, Venkataraman S, Alimova I, Birks DK, Donson AM, Knipstein J, et al. Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells. BMC Cancer 2012; 12:80; http://dx.doi.org/10.1186/1471-2407-12-80; PMID: 22390279
   PubMed Web of Science ®Google Scholar
• Qian Y, Hua E, Bisht K, Woditschka S, Skordos KW, Liewehr DJ, et al. Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain. Clin Exp Metastasis 2011; 28:899 - 908; http://dx.doi.org/10.1007/s10585-011-9421-9; PMID: 21953073
   PubMed Web of Science ®Google Scholar
• De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, et al. Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer “unfit” for cisplatin-based chemotherapy: phase II--results of EORTC study 30986. J Clin Oncol 2009; 27:5634 - 9; http://dx.doi.org/10.1200/JCO.2008.21.4924; PMID: 19786668
   PubMed Web of Science ®Google Scholar
• Schöffski P, Blay JY, De Greve J, Brain E, Machiels JP, Soria JC, et al. Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). Eur J Cancer 2010; 46:2206 - 15; http://dx.doi.org/10.1016/j.ejca.2010.03.039; PMID: 20471824
   PubMed Web of Science ®Google Scholar
• Haupenthal J, Bihrer V, Korkusuz H, Kollmar O, Schmithals C, Kriener S, et al. Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels. Neoplasia 2012; 14:410 - 9; PMID: 22745587
   PubMed Web of Science ®Google Scholar
• Schöffski P, Awada A, Dumez H, Gil T, Bartholomeus S, Wolter P, et al. A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer 2012; 48:179 - 86; http://dx.doi.org/10.1016/j.ejca.2011.11.001; PMID: 22119200
   PubMed Web of Science ®Google Scholar
• Olmos D, Barker D, Sharma R, Brunetto AT, Yap TA, Taegtmeyer AB, et al. Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res 2011; 17:3420 - 30; http://dx.doi.org/10.1158/1078-0432.CCR-10-2946; PMID: 21459796
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25:402 - 8; http://dx.doi.org/10.1006/meth.2001.1262; PMID: 11846609
   PubMed Web of Science ®Google Scholar
• Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc 2006; 1:2315 - 9; http://dx.doi.org/10.1038/nprot.2006.339; PMID: 17406473
   PubMed Web of Science ®Google Scholar
• Lee YJ, Shacter E. Oxidative stress inhibits apoptosis in human lymphoma cells. J Biol Chem 1999; 274:19792 - 8; http://dx.doi.org/10.1074/jbc.274.28.19792; PMID: 10391922
   PubMed Web of Science ®Google Scholar
• Pauwels B, Korst AE, de Pooter CM, Pattyn GG, Lambrechts HA, Baay MF, et al. Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies. Cancer Chemother Pharmacol 2003; 51:221 - 6; PMID: 12655440
   PubMed Web of Science ®Google Scholar
• Tao Y, Zhang P, Frascogna V, Lecluse Y, Auperin A, Bourhis J, et al. Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells. Br J Cancer 2007; 97:1664 - 72; http://dx.doi.org/10.1038/sj.bjc.6604083; PMID: 18026198
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27 - 55; http://dx.doi.org/10.1016/0065-2571(84)90007-4; PMID: 6382953
   PubMedGoogle Scholar